Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell

Open access

Abstract

Recent studies have demonstrated that the antitumor immunity of immune cells can be modulated by gut microbiota and their metabolites. However, the underlying mechanisms remain unclear. Here, we showed that the serum butyric acid level is positively correlated with the expression of programmed cell death-1 (PD-1) on circulating CD8+ and Vγ9 Vδ2 (Vδ2+) T cells in patients with non-small cell lung cancer (NSCLC). Responder NSCLC patients exhibited higher levels of serum acetic acid, propionic acid, and butyric acid than non-responders. Depletion of the gut microbiota reduces butyrate levels in both feces and serum in tumor-bearing mice. Mechanistically, butyrate increased histone 3 lysine 27 acetylation (H3K27ac) at the promoter region of Pdcd1 and Cd28 in human CD8+ T cells, thereby promoting the expression of PD-1/CD28 and enhancing the efficacy of anti-PD-1 therapy. Butyrate supplementation promotes the expression of antitumor cytokines in cytotoxic CD8+ T cells by modulating the T-cell receptor (TCR) signaling pathway. Collectively, our findings reveal that the metabolite butyrate of the gut microbiota facilitates the efficacy of anti-PD-1 immunotherapy by modulating TCR signaling of cytotoxic CD8 T cells, and is a highly promising therapeutic biomarker for enhancing antitumor immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19490976.2023.2249143

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Serum butyric acid amount is correlated with anti-PD-1 efficacy in NSCLC patients. (a) Overview of experimental design. Targeted metabolomics (GC-MS/MS) analysis procedure. (b, c) the serum levels of acetic acid (AA), propionic acid (PA), isobutyric acid (IBA), butyric acid (BA), isovaleric acid (IVA), valeric acid (VA) and caproic acid (CA) in NSCLC patients were detected by GC-MS/MS (n = 22). (d) Linear regression analysis between SCFAs (AA, PA, IBA, BA, IVA, VA and CA) levels and surface markers (PD-1+, Tim-3+, TIGIT+, CD28+) on T cells (CD4+, CD8+, Vδ1+, and Vδ2+) in patients with advanced lung cancer (n = 22). (e) experimental design. SCFAs levels in serum of patients with NSCLC were detected by GC-MS/MS before therapy with anti-PD-1 and chemotherapy. (f) CT scans showing changes of tumor size in patients with NSCLC who received intravenous anti-PD-1 and chemotherapy. (g) the serum SCFAs from patients with NSCLC were measured and compared between responders (complete response, partial response or stable disease; CR, PR or SD) and non-responders (progressive disease, PD or death). (h) the level of PD-1 on circulating CD8+ and Vδ2+ T cells in responders (N) versus non-responders (NR) of NSCLC (N, n = 11; NR, n = 11). The Pearson correlation was used in (d); two-tailed unpaired Student’s t-test (g and h). Data represented mean or mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.
Figure 1. Serum butyric acid amount is correlated with anti-PD-1 efficacy in NSCLC patients. (a) Overview of experimental design. Targeted metabolomics (GC-MS/MS) analysis procedure. (b, c) the serum levels of acetic acid (AA), propionic acid (PA), isobutyric acid (IBA), butyric acid (BA), isovaleric acid (IVA), valeric acid (VA) and caproic acid (CA) in NSCLC patients were detected by GC-MS/MS (n = 22). (d) Linear regression analysis between SCFAs (AA, PA, IBA, BA, IVA, VA and CA) levels and surface markers (PD-1+, Tim-3+, TIGIT+, CD28+) on T cells (CD4+, CD8+, Vδ1+, and Vδ2+) in patients with advanced lung cancer (n = 22). (e) experimental design. SCFAs levels in serum of patients with NSCLC were detected by GC-MS/MS before therapy with anti-PD-1 and chemotherapy. (f) CT scans showing changes of tumor size in patients with NSCLC who received intravenous anti-PD-1 and chemotherapy. (g) the serum SCFAs from patients with NSCLC were measured and compared between responders (complete response, partial response or stable disease; CR, PR or SD) and non-responders (progressive disease, PD or death). (h) the level of PD-1 on circulating CD8+ and Vδ2+ T cells in responders (N) versus non-responders (NR) of NSCLC (N, n = 11; NR, n = 11). The Pearson correlation was used in (d); two-tailed unpaired Student’s t-test (g and h). Data represented mean or mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.CC BY · PubMed Central
Figure 2. Depletion of gut microbiota decreases the levels of butyric acid and acetic acid both in fecal and serum of tumor-bearing mice. (a) experimental design: mice were treated with antibiotics (ABX, n = 6 per group) or drinking water (water, n = 6 per group), and inoculated with B16-F0 tumor cells. Feces and serum of the mice were collected on day 15. (b) Cluster heat map of species abundance (p, Phylum; c, class; o, Order; f, family; g, Genus; s, species). (c) relative abundance in water versus ABX of OTU (16S sequencing, based on Metastats analysis). (d) Taxonomic cladogram from LEfSe analysis (n = 6). The species without significant difference are uniformly colored yellow, and the difference species biomarker is colored following the group (red=ABX, green=Water). (e, f) targeted metabolomics analysis of gut microbial metabolites (AA, PA, and BA) in colon contents (feces) and serum from mice with or without ABX treatment (n = 6 per group). Two-tailed unpaired Student’s t-test (c, e, and f). *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.
Figure 2. Depletion of gut microbiota decreases the levels of butyric acid and acetic acid both in fecal and serum of tumor-bearing mice. (a) experimental design: mice were treated with antibiotics (ABX, n = 6 per group) or drinking water (water, n = 6 per group), and inoculated with B16-F0 tumor cells. Feces and serum of the mice were collected on day 15. (b) Cluster heat map of species abundance (p, Phylum; c, class; o, Order; f, family; g, Genus; s, species). (c) relative abundance in water versus ABX of OTU (16S sequencing, based on Metastats analysis). (d) Taxonomic cladogram from LEfSe analysis (n = 6). The species without significant difference are uniformly colored yellow, and the difference species biomarker is colored following the group (red=ABX, green=Water). (e, f) targeted metabolomics analysis of gut microbial metabolites (AA, PA, and BA) in colon contents (feces) and serum from mice with or without ABX treatment (n = 6 per group). Two-tailed unpaired Student’s t-test (c, e, and f). *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.CC BY · PubMed Central
Figure 3. Butyrate supplementation enhances the antitumor immune responses of anti-PD-1. (a) Overview of study design. (b, c) BA pretreated Vδ2 T cells (effector, E) were incubated with Jurkat cells (target, T) at the indicated ratios for 6 hours with or without anti-PD-1 treatment, and the percentages of dead cells out of total target cells identified as PI+ were shown (healthy donors, n = 3 per group). (d) experiment approach. (e) images of B16-F0 tumors in mice at day 15 post-tumor implantation. (f) tumor weight in the mice in each group at the end of experiment (n = 6 per group). (g-i) tumor growth (g and h) and survival curves (i) in the mice after treatment with IgG, butyrate, anti-PD-1 alone or the combination (n = 6 per group). (j) Tissue pathology of the indicated organs was evaluated by H&E staining at the end of the experiment (days 15 after B16-F0 tumor implantation). (k-m) tumor-infiltrating IFN-γ+ and TNF-α+ T cells (CD8+ and CD4+) were analyzed by flow cytometry (n = 6 per group). Two-tailed unpaired Student’s t-test used in (c, E:T = 15:1); one-way ANOVA with Tukey’s multiple comparisons test (f, g, l and m); log-rank (Mantel-Cox) test was used in (i). Data represented mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.
Figure 3. Butyrate supplementation enhances the antitumor immune responses of anti-PD-1. (a) Overview of study design. (b, c) BA pretreated Vδ2 T cells (effector, E) were incubated with Jurkat cells (target, T) at the indicated ratios for 6 hours with or without anti-PD-1 treatment, and the percentages of dead cells out of total target cells identified as PI+ were shown (healthy donors, n = 3 per group). (d) experiment approach. (e) images of B16-F0 tumors in mice at day 15 post-tumor implantation. (f) tumor weight in the mice in each group at the end of experiment (n = 6 per group). (g-i) tumor growth (g and h) and survival curves (i) in the mice after treatment with IgG, butyrate, anti-PD-1 alone or the combination (n = 6 per group). (j) Tissue pathology of the indicated organs was evaluated by H&E staining at the end of the experiment (days 15 after B16-F0 tumor implantation). (k-m) tumor-infiltrating IFN-γ+ and TNF-α+ T cells (CD8+ and CD4+) were analyzed by flow cytometry (n = 6 per group). Two-tailed unpaired Student’s t-test used in (c, E:T = 15:1); one-way ANOVA with Tukey’s multiple comparisons test (f, g, l and m); log-rank (Mantel-Cox) test was used in (i). Data represented mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.CC BY · PubMed Central
Figure 4. Microbial metabolites butyrate promotes anti-PD-1 immunotherapy efficacy through CD8+ T cell-dependent antitumor immunity. (a) experimental design: mice were treated with antibiotics, and inoculated with B16-F0 tumor cells followed by indicated therapy. (b-e) tumor growth was monitored. Mice were inoculated with B16-F0 in ABX pretreated mice, then received anti-PD-1, BA, or anti-PD-1 plus butyrate therapy (n = 7 per group). Experiments were independently repeated three times (b-e). (f, g) serum IFN-γ and TNF-α levels in mice were measured by ELISA after indicated treatment (mice serum were collected on day 18), n = 7 per group. One-way ANOVA with Tukey’s multiple comparisons test (e-g). Data represented mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.
Figure 4. Microbial metabolites butyrate promotes anti-PD-1 immunotherapy efficacy through CD8+ T cell-dependent antitumor immunity. (a) experimental design: mice were treated with antibiotics, and inoculated with B16-F0 tumor cells followed by indicated therapy. (b-e) tumor growth was monitored. Mice were inoculated with B16-F0 in ABX pretreated mice, then received anti-PD-1, BA, or anti-PD-1 plus butyrate therapy (n = 7 per group). Experiments were independently repeated three times (b-e). (f, g) serum IFN-γ and TNF-α levels in mice were measured by ELISA after indicated treatment (mice serum were collected on day 18), n = 7 per group. One-way ANOVA with Tukey’s multiple comparisons test (e-g). Data represented mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.CC BY · PubMed Central
Figure 5. Butyrate acts within activated T cells to enhance acetylation of the Pdcd1 and Cd28 locus. (a) mRNA levels of immune checkpoint receptors and co-stimulatory molecules in SCFAs (AA = 10 mM, PA = 1 mM and BA = 0.5 mM) pretreated CD8+ T cells were verified by Quantitative real-time PCR (qPCR), and their fold changes were shown in heat map (healthy donors, n = 3 per group). (b, c) the expression of PD-1+ and CD28+ on vehicle, AA, PA, BA-pretreated Vδ2+ and CD8+ T cells was analyzed by flow cytometry (Vδ2+, n = 12; CD8+, n = 5). (d-f) human cytotoxic T cells (CD8+ and Vδ2+) were treated with BA, A-485 (1 μM) alone or the combination for 48 hours followed by flow cytometry (n = 3–7). (g) the levels of histone 3 lysine 9 acetylation (H3K9ac) and histone 3 lysine 27 acetylation (H3K27ac) in vehicle or BA-treated cytotoxic CD8+ T cells were determined by immunoblotting. (h) CD8+ T cells were treated with or without A485, BA or their combination for 48 hours, followed by western blot. (i-m) Overview of primers design (i). Graph showed ChIP-qPCR analysis of H3K27ac and H3K9ac at the promoter of Cd28 and Pdcd1 gene in vehicle or BA-pretreated CD8+ T cells. The levels of H3K9ac (j and k) and H3K27ac (l and m) were normalized to the input, n = 3 healthy donors. Primers 1–7 (qPCR primers for Cd28 and Pdcd1 1 to 7). Two-tailed unpaired Student’s t-test (b and c); one-way ANOVA with Tukey’s multiple comparisons test (e and f). Data represented mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.
Figure 5. Butyrate acts within activated T cells to enhance acetylation of the Pdcd1 and Cd28 locus. (a) mRNA levels of immune checkpoint receptors and co-stimulatory molecules in SCFAs (AA = 10 mM, PA = 1 mM and BA = 0.5 mM) pretreated CD8+ T cells were verified by Quantitative real-time PCR (qPCR), and their fold changes were shown in heat map (healthy donors, n = 3 per group). (b, c) the expression of PD-1+ and CD28+ on vehicle, AA, PA, BA-pretreated Vδ2+ and CD8+ T cells was analyzed by flow cytometry (Vδ2+, n = 12; CD8+, n = 5). (d-f) human cytotoxic T cells (CD8+ and Vδ2+) were treated with BA, A-485 (1 μM) alone or the combination for 48 hours followed by flow cytometry (n = 3–7). (g) the levels of histone 3 lysine 9 acetylation (H3K9ac) and histone 3 lysine 27 acetylation (H3K27ac) in vehicle or BA-treated cytotoxic CD8+ T cells were determined by immunoblotting. (h) CD8+ T cells were treated with or without A485, BA or their combination for 48 hours, followed by western blot. (i-m) Overview of primers design (i). Graph showed ChIP-qPCR analysis of H3K27ac and H3K9ac at the promoter of Cd28 and Pdcd1 gene in vehicle or BA-pretreated CD8+ T cells. The levels of H3K9ac (j and k) and H3K27ac (l and m) were normalized to the input, n = 3 healthy donors. Primers 1–7 (qPCR primers for Cd28 and Pdcd1 1 to 7). Two-tailed unpaired Student’s t-test (b and c); one-way ANOVA with Tukey’s multiple comparisons test (e and f). Data represented mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.CC BY · PubMed Central
Figure 6. Butyrate regulates the function of CD8+ T cells through T cell receptor signaling. (a) vehicle, AA (10 mM), PA (1 mM) or BA (0.5 mM)-pretreated human CD8+ T cells were activated with or without α-CD3/CD28 for 4 hours. The expression of various genes related to antitumor immunity in CD8+ T cells was measured by qPCR, and their fold changes were shown in heat map (healthy donors, n = 3 per group). (b-e) AA, PA, BA or control-pretreated CD8+ and Vδ2+ T cells were stimulated with α-CD3/CD28 for 4 hours, and the levels of IFN-γ+ and TNF-α+ in Vδ2+ and CD8+ T cells were detected by flow cytometry (n = 3–5). (f) immunoblotting analysis the phosphorylation of protein from T cell receptor signaling pathway in vehicle or BA-pretreated CD8+ T cells upon α-CD3/CD28 activation. (g, h) BA or vehicle-pretreated CD8+ T cells were preloaded with fluo-3 AM in Ca2+ free medium, then those cells were activated by α-CD3/CD28 or PMA/Ion with or without Ca2+ supplementation. Ca2+ fluorescence intensity (MFI) transformation was detected by flow cytometry. (i, j) BA-pretreated or vehicle Vδ2+ and CD8+ T cells were treated with BA, U73122 alone or BA+U73122 for another 1 hour, and then immunoblot analysis the expression of PLCγ1 and p-PLCγ1 from whole-cell lysate. (k-n) BA or vehicle-pretreated Vδ2+ and CD8+ T cells were treated with or without U73122 under the condition of α-CD3/CD28 activation for 4 hours. IFN-γ+ and TNF-α+ CD8+ or Vδ2+ T cells were measured by flow cytometry (n = 6). Two-tailed unpaired Student’s t-test (c and e); one-way ANOVA with Tukey’s multiple comparisons test (l and n). Data represented mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.
Figure 6. Butyrate regulates the function of CD8+ T cells through T cell receptor signaling. (a) vehicle, AA (10 mM), PA (1 mM) or BA (0.5 mM)-pretreated human CD8+ T cells were activated with or without α-CD3/CD28 for 4 hours. The expression of various genes related to antitumor immunity in CD8+ T cells was measured by qPCR, and their fold changes were shown in heat map (healthy donors, n = 3 per group). (b-e) AA, PA, BA or control-pretreated CD8+ and Vδ2+ T cells were stimulated with α-CD3/CD28 for 4 hours, and the levels of IFN-γ+ and TNF-α+ in Vδ2+ and CD8+ T cells were detected by flow cytometry (n = 3–5). (f) immunoblotting analysis the phosphorylation of protein from T cell receptor signaling pathway in vehicle or BA-pretreated CD8+ T cells upon α-CD3/CD28 activation. (g, h) BA or vehicle-pretreated CD8+ T cells were preloaded with fluo-3 AM in Ca2+ free medium, then those cells were activated by α-CD3/CD28 or PMA/Ion with or without Ca2+ supplementation. Ca2+ fluorescence intensity (MFI) transformation was detected by flow cytometry. (i, j) BA-pretreated or vehicle Vδ2+ and CD8+ T cells were treated with BA, U73122 alone or BA+U73122 for another 1 hour, and then immunoblot analysis the expression of PLCγ1 and p-PLCγ1 from whole-cell lysate. (k-n) BA or vehicle-pretreated Vδ2+ and CD8+ T cells were treated with or without U73122 under the condition of α-CD3/CD28 activation for 4 hours. IFN-γ+ and TNF-α+ CD8+ or Vδ2+ T cells were measured by flow cytometry (n = 6). Two-tailed unpaired Student’s t-test (c and e); one-way ANOVA with Tukey’s multiple comparisons test (l and n). Data represented mean±SD. *P < .05, **P < .01, ***P < .001, ****P < .0001. n.s., not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. 10.1126/science.aaf0683 · DOI · Paper page

Cited by

See all 221

Metadata

Authors
Zhu, X., Li, K., Liu, G., Wu, R., Zhang, Y., Wang, S., Xu, M., Lu, L., & Li, P.
Affiliations
  • Jinan University (CN)
  • Sun Yat-sen University (CN)
  • Anhui Provincial Center for Disease Control and Prevention (CN)
Corresponding author
  • Xu, Meng
  • Lu, Ligong
  • Li, Peng
Venue
Gut Microbes
Published
2023-08-27
Volume
15
Issue
2
Pages
2249143-2249143
ISSN
  • 1949-0976 (ISSN-L)
  • 1949-0984
OpenAlex
W4386208749
Cited by
220
References
48
Citations by year
2026: 85 · 2025: 86 · 2024: 48 · 2023: 1
FWCI
26.96
Type
journal article
Language
en
Open access
Locations
  • Gut Microbes (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • China Postdoctoral Science Foundation (2022M713670)
  • Guangdong Basic and Applied Basic Research Foundation (2022A1515110416)
  • Medical Scientific Research Foundation of Guangdong Province (A2022417)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
butyrate, gut microbiota metabolites, anti-PD-1 therapy, PD-1, CD8+ T cells, T cell receptor signaling, non-small cell lung cancer, H3K27 acetylation, PDCD1, CD28, antitumor immunity, short-chain fatty acids, immunotherapy response biomarkers, gut microbiota depletion
MeSH terms
Gastrointestinal Microbiome, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Receptors, Antigen, T-Cell, Signal Transduction, CD28 Antigens, CD8-Positive T-Lymphocytes, Butyric Acid, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. https://app.cochat.ai/papers/10.1080/19490976.2023.2249143
The paper
Zhu, X., Li, K., Liu, G., Wu, R., Zhang, Y., Wang, S., Xu, M., Lu, L., & Li, P. (2023). Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. Gut Microbes. https://doi.org/10.1080/19490976.2023.2249143

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.